

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE.....	2
SCOPE AND FORMAT OF REPORT	2
METHODOLOGY	2
INFORMATION SOURCES.....	3
ANALYST'S CREDENTIALS.....	3
RELATED BCC REPORTS	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	4
CHAPTER TWO: SUMMARY.....	5
SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH 2016 (\$ MILLIONS)	5
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2010-2016 (\$ MILLIONS).....	6
SUMMARY (CONTINUED)	7
CHAPTER THREE: OVERVIEW	8
INTRODUCTION	8
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION.....	9
BIOCHIP TYPES	9
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES.....	10
TABLE 3 BIOCHIP NOMENCLATURE.....	11
SCOPE OF REPORT	12
TABLE 4 SCOPE OF REPORT.....	12
MARKET POTENTIAL OF BIOCHIPS.....	12
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TECHNOLOGY, THROUGH 2016 (\$ MILLIONS).....	13
TABLE 6 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY FUNCTION, THROUGH 2016 (\$ MILLIONS)	14
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS.....	15
TABLE 7 FORCES DRIVING BIOCHIPS GROWTH.....	15
GROWTH IN LIFE SCIENCE R&D FUNDING	16
TABLE 8 2009-2010 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, (\$ MILLIONS).....	16
LARGE-SCALE GENOMIC, PROTEOMIC AND BIOCHIP INITIATIVES.....	17
DEVELOPMENT OF TARGETED, PERSONALIZED MEDICINES	17
COST CONSCIOUS HEALTHCARE SYSTEM.....	18
RAPIDLY AGING POPULATION IN DEVELOPED REGIONS	18

NEED FOR MORE INNOVATIVE DIAGNOSTIC TESTING FORMATS	18
ONGOING DISCOVERIES IN GENOMICS AND PROTEOMICS	19
DISCOVERY OF GENE AND SNP DISEASE ASSOCIATIONS	19
THE BIOCHIP INDUSTRY	19
<i>TABLE 9 COMPARISON OF BIOCHIPS INDUSTRIES</i>	20
CHAPTER FOUR: MICROARRAY TECHNOLOGIES	21
INTRODUCTION	21
THE NANOSCALE WORLD	21
<i>TABLE 10 THE NANOSCALE WORLD</i>	21
<i>TABLE 11 MICROARRAY TYPES</i>	22
<i>TABLE 12 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES</i>	22
<i>TABLE 12 (CONTINUED)</i>	23
DNA MICROARRAY TECHNOLOGIES	24
INTRODUCTION	24
<i>FIGURE 1 MICROARRAY FEATURE DENSITY</i>	24
<i>FIGURE 2 MICROARRAY RESOLUTION</i>	25
<i>TABLE 13 MICROARRAY GENOME CONTENT</i>	26
<i>TABLE 14 DNA MICROARRAY PLATFORM FEATURES</i>	26
Introduction (Continued)	27
<i>TABLE 15 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS</i>	28
Introduction (Continued)	29
STEPS IN THE DNA MICROARRAY EXPERIMENT	30
DNA MICROARRAY APPLICATIONS	30
<i>TABLE 16 DNA MICROARRAY APPLICATIONS</i>	31
<i>TABLE 17 GENETIC ANALYSIS TECHNOLOGIES COMPARISON</i>	32
DNA Microarray Applications	33
<i>FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1</i>	34
SNP ANALYSIS	34
<i>TABLE 18 SNP MEASUREMENT PLATFORMS</i>	35
EPIGENETIC ANALYSIS	35
Epigenetic Analysis (Continued)	36
<i>FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS</i>	37
ChIP-Chip	37
CYTOGENETIC ANALYSIS	38
<i>TABLE 19 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES</i>	39
MICRO-RNA ANALYSIS	40
<i>TABLE 20 WORKFLOW FOR A MICRO-RNA EXPERIMENT</i>	41

ARRAYS ON BEADS	42
<i>TABLE 21 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS</i>	42
CATALOG AND CUSTOM DNA MICROARRAYS	43
SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS	43
TOXICOGENOMICS	44
PROTEIN MICROARRAY TECHNOLOGIES	45
INTRODUCTION.....	45
<i>FIGURE 5 IMPORTANCE OF PROTEINS</i>	45
PROTEOMICS WORKFLOW	46
<i>FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED</i>	47
PROTEIN MICROARRAY DESIGN FEATURES	47
<i>TABLE 22 PROTEIN MICROARRAY PLATFORMS</i>	47
Protein Microarray Design Features (Continued)	48
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS.....	49
<i>TABLE 23 PROTEIN MICROARRAYS AS RESEARCH TOOLS</i>	49
PROTEIN MICROARRAY TYPES	50
<i>TABLE 24 PROTEIN MICROARRAY PRODUCT TYPES</i>	50
<i>TABLE 24 (CONTINUED)</i>	51
Protein Microarray Types (Continued).....	52
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES	53
<i>TABLE 25 PROTEIN MICROARRAY TECHNICAL CHALLENGES</i>	53
Protein Microarray Technology ... (Continued)	54
EMERGING MICROARRAY TECHNOLOGIES	55
<i>TABLE 26 EMERGING MICROARRAY TECHNOLOGIES</i>	56
GLYCOMICS MICROARRAYS	56
TISSUE MICROARRAYS	57
Tissue Microarrays (Continued)	58
CHAPTER FIVE: LAB-ON-A-CHIP TECHNOLOGIES	59
INTRODUCTION	59
<i>TABLE 27 LOAC PRODUCT LIFE CYCLE STAGE</i>	59
<i>TABLE 28 LOAC SUBSTRATE TECHNOLOGIES</i>	60
LOAC TYPES	61
<i>TABLE 29 LOAC TYPES</i>	61
<i>IN VITRO</i> PROTEOMICS	61
ELECTROPHORESIS ON A CHIP	62
STRUCTURAL PROTEOMICS	62
PCR ON A CHIP	63
IMMUNOASSAYS ON A CHIP	64
MS ON CHIP	65
SEQUENCING ON CHIP	66
<i>TABLE 30 WORKFLOW COMPARISON OF SELECTED NEXT- GENERATION DNA SEQUENCING PLATFORMS</i>	66

<i>TABLE 31 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES</i>	67
Sequencing On Chip (Continued)	68
LOAC APPLICATIONS	69
<i>TABLE 32 LOAC MARKET SEGMENTS</i>	69
<i>TABLE 33 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS</i>	70
LOAC KEY TECHNOLOGY TRENDS	71
<i>TABLE 34 LOAC KEY TECHNOLOGY TRENDS</i>	71
LOAC KEY TECHNOLOGY TRENDS (CONTINUED).....	72
<i>TABLE 35 LOAC TECHNOLOGY PLATFORMS</i>	73
LOAC TECHNOLOGY CHALLENGES	74
<i>TABLE 36 LOAC TECHNOLOGY CHALLENGES</i>	74
LOAC TECHNOLOGY CHALLENGES (CONTINUED)	75
CHAPTER SIX: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	76
BIOCHIP MARKET SEGMENTATION	76
<i>TABLE 37 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS</i>	76
DRUG DISCOVERY AND DEVELOPMENT	77
DRUG INDUSTRY CHALLENGES	78
OVERVIEW OF THE DRUG DISCOVERY AND DEVELOPMENT PROCESS.....	78
<i>FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE</i>	79
<i>TABLE 38 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT</i>	80
DRUG TARGET IDENTIFICATION	81
DRUG DISCOVERY.....	82
Structural Biology	82
Lead Generation	82
Lead Generation (Continued).....	83
Lead Generation (Continued).....	84
Lead Optimization	85
Process R&D	86
Preclinical and Clinical Trials	86
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS.....	87
<i>TABLE 39 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT</i>	87
Needs in the Drug Discovery and ... (Continued).....	88
Needs in the Drug Discovery and ... (Continued).....	89
<i>FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS</i>	90
CHAPTER SEVEN: BIOCHIPS DIAGNOSTICS APPLICATIONS	91
INTRODUCTION	91
<i>TABLE 40 DIAGNOSTICS PARADIGM SHIFT</i>	91

HOW DIAGNOSTICS ARE DIFFERENT THAN RESEARCH TOOLS	92
<i>TABLE 41 REQUIREMENTS FOR AN EPIGENETICS BISULFITE</i>	
<i>DIAGNOSTIC ASSAY</i>	92
HOW BIOLOGICAL CONTENT DRIVES DIAGNOSTICS' GROWTH.....	93
<i>TABLE 42 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS</i>	94
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED	
TESTS	95
<i>TABLE 43 RATE OF ADOPTION OF DNA MICROARRAY</i>	
<i>DIAGNOSTICS TESTS</i>	96
MOLECULAR DIAGNOSTICS	97
INTRODUCTION.....	97
MARKET CHALLENGES FOR DNA-BASED MDX	
PLATFORMS	98
<i>TABLE 44 COMPARISON OF DNA-BASED MDX PLATFORMS</i>	99
<i>TABLE 45 FACTORS AFFECTING PENETRATION OF NEXT-</i>	
<i>GENERATION FORMATS INTO THE MDX MARKET</i>	100
Market Challenges for DNA-based MDx Platforms	
(Continued)	101
DIAGNOSTICS MARKET SEGMENTS	102
TEST SENSITIVITY AND SPECIFICITY	103
<i>FIGURE 9 SENSITIVITY AND SPECIFICITY</i>	104
REGULATORY STATUS.....	105
CANCER APPLICATIONS OF BIOCHIPS	106
CANCER OVERVIEW	106
<i>TABLE 46 ESTIMATED U.S. INCIDENCE FOR SELECTED CANCERS,</i>	
<i>2010</i>	106
BLADDER CANCER.....	107
<i>TABLE 47 STATUS OF ADVANCED BLADDER CANCER</i>	
<i>DIAGNOSTICS</i>	107
Bladder Cancer (Continued)	108
BREAST CANCER.....	109
Breast Cancer Screening.....	109
Prognosis and Pharmacogenetics Tests.....	110
<i>TABLE 48 ESTIMATED NUMBER OF ANNUAL BREAST CANCER</i>	
<i>TREATMENT DECISIONS IN THE U.S. BY CANCER</i>	
<i>CLASSIFICATION</i>	110
Breast Cancer MDx Platforms	111
<i>TABLE 49 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	111
<i>TABLE 50 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS</i>	112
<i>TABLE 50 (CONTINUED)</i>	113
Breast Cancer MDx Platforms (Continued).....	114
Breast Cancer MDx Platforms (Continued).....	115
Breast Cancer MDx Platforms (Continued).....	116
BRAIN CANCER.....	117

<i>TABLE 51 STATUS OF ADVANCED BRAIN CANCER DIAGNOSTICS.....</i>	<i>118</i>
CERVICAL CANCER.....	118
Cervical Cancer (Continued).....	119
<i>TABLE 52 STATUS OF ADVANCED HPV DIAGNOSTICS.....</i>	<i>120</i>
Cervical Cancer (Continued).....	121
COLORECTAL CANCER	122
Conventional Colorectal Cancer Screening Tests	123
<i>TABLE 53 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR</i>	
<i>COLORECTAL CANCER.....</i>	<i>123</i>
Molecular Colorectal Cancer Diagnostics Tests	124
<i>TABLE 54 STATUS OF ADVANCED COLORECTAL CANCER</i>	
<i>DIAGNOSTICS.....</i>	<i>125</i>
Molecular Colorectal ... (Continued).....	126
Molecular Colorectal ... (Continued).....	127
CUP	128
CUP (Continued)	129
<i>TABLE 55 STATUS OF ADVANCED CUP DIAGNOSTICS.....</i>	<i>130</i>
GASTRIC CANCER	131
<i>TABLE 56 STATUS OF GASTRIC/STOMACH CANCER NEXT-</i>	
<i>GENERATION DX TESTS</i>	<i>132</i>
KIDNEY CANCER.....	133
<i>TABLE 57 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS.....</i>	<i>133</i>
LEUKEMIA	134
<i>TABLE 58 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS.....</i>	<i>134</i>
<i>TABLE 58 (CONTINUED).....</i>	<i>135</i>
Leukemia (Continued).....	136
LIVER CANCER	137
<i>TABLE 59 STATUS OF LIVER CANCER NEXT-GENERATION DX</i>	
<i>TESTS.....</i>	<i>137</i>
LYMPHOMA CANCERS	138
<i>TABLE 60 STATUS OF ADVANCED LYMPHOMA CANCER</i>	
<i>DIAGNOSTICS.....</i>	<i>139</i>
LUNG CANCER.....	139
<i>TABLE 61 5-YEAR SURVIVAL RATES FOR NONSMALL CELL LUNG</i>	
<i>CANCER (%).....</i>	<i>140</i>
<i>TABLE 62 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS.....</i>	<i>141</i>
<i>TABLE 62 (CONTINUED).....</i>	<i>142</i>
Lung Cancer (Continued).....	143
Lung Cancer (Continued).....	144
MELANOMA	145
<i>TABLE 63 STATUS OF ADVANCED MELANOMA DIAGNOSTICS.....</i>	<i>145</i>
Melanoma (Continued).....	146
OVARIAN CANCER	147
<i>TABLE 64 EARLY SCREENING OVARIAN CANCER TESTS.....</i>	<i>147</i>

<i>TABLE 65 STATUS OF ADVANCED OVARIAN CANCER</i>	
<i>DIAGNOSTICS</i>	148
Ovarian Cancer (Continued).....	149
PANCREATIC CANCER.....	150
<i>TABLE 66 STATUS OF ADVANCED PANCREATIC CANCER</i>	
<i>DIAGNOSTICS</i>	150
PROSTATE CANCER.....	151
<i>TABLE 67 STATUS OF ADVANCED PROSTATE CANCER</i>	
<i>DIAGNOSTICS</i>	152
<i>TABLE 67 (CONTINUED)</i>	153
Prostate Cancer (Continued).....	154
Prostate Cancer (Continued).....	155
THYROID CANCER.....	156
<i>TABLE 68 STATUS OF ADVANCED THYROID CANCER</i>	
<i>DIAGNOSTICS</i>	156
SUMMARY OF ADVANCED CANCER DIAGNOSTICS.....	157
<i>TABLE 69 NEXT-GENERATION DX TEST SUMMARY BY</i>	
<i>INDICATION AND BY TECHNOLOGY</i>	157
BIOCHIPS APPLICATIONS IN WARFARIN SENSITIVITY.....	158
<i>TABLE 70 IMPORTANCE OF CYP GENES IN DRUG METABOLISM</i>	159
<i>TABLE 71 STATUS OF ADVANCED WARFARIN CYP</i>	
<i>PHARMACOGENETIC DIAGNOSTICS</i>	160
<i>TABLE 71 (CONTINUED)</i>	161
BIOCHIPS APPLICATIONS IN WARFARIN ... (CONTINUED).....	162
BIOCHIPS APPLICATIONS IN INFECTIOUS DISEASE	
<i>DIAGNOSTICS</i>	163
TUBERCULOSIS.....	163
HOSPITAL-ACQUIRED INFECTIONS.....	164
<i>TABLE 72 STATUS OF MRSA AND C. DIFFICILE ADVANCED</i>	
<i>DIAGNOSTICS</i>	165
INFLUENZA.....	166
<i>TABLE 73 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS</i>	166
<i>TABLE 73 (CONTINUED)</i>	167
SEXUALLY TRANSMITTED DISEASES.....	168
<i>TABLE 74 STATUS OF CHLAMYDIA TRACHOMATIS AND</i>	
<i>NEISSERIA GONORRHEA (CT/NG) ADVANCED DIAGNOSTICS</i>	169
OTHER INFECTIOUS DISEASES.....	169
BIOCHIPS APPLICATIONS IN NEUROLOGICAL DIAGNOSTICS.....	170
ALZHEIMER'S DISEASE.....	170
<i>TABLE 75 ALZHEIMER'S DISEASE DIAGNOSTICS APPROACHES</i>	171
<i>TABLE 76 STATUS OF ALZHEIMER'S DISEASE ADVANCED</i>	
<i>DIAGNOSTICS TESTS</i>	172
SCHIZOPHRENIA.....	173
BIOCHIPS APPLICATIONS IN CARDIAC DIAGNOSTICS.....	174

CONGESTIVE HEART FAILURE.....	174
<i>TABLE 77 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE</i>	<i>175</i>
OTHER CARDIAC DIAGNOSTICS	176
BIOCHIP APPLICATIONS IN CYSTIC FIBROSIS DIAGNOSTICS	177
<i>TABLE 78 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS</i>	<i>177</i>
BIOCHIP APPLICATIONS IN CYSTIC ... (CONTINUED)	178
BIOCHIPS APPLICATIONS IN PRE- AND POSTNATAL SCREENING	179
<i>TABLE 79 PRENATAL DIAGNOSTICS TESTS</i>	<i>180</i>
BIOCHIPS APPLICATIONS IN PRE- AND ... (CONTINUED).....	181
BIOCHIPS APPLICATIONS IN IMMUNE DISEASE DIAGNOSTICS	182
HLA TYPING TESTS	182
<i>TABLE 80 HLA TESTING MARKET</i>	<i>183</i>
AUTOIMMUNE TESTING.....	184
BIOCHIP APPLICATIONS FOR AG-BIO MARKET.....	185
<i>TABLE 81 BIOCHIPS IN AG-BIO MARKET</i>	<i>186</i>
BIOCHIP APPLICATIONS FOR AG-BIO ... (CONTINUED)	187
CHAPTER EIGHT: BIOCHIPS INDUSTRY	188
ACQUISITIONS.....	188
<i>TABLE 82 RECENT ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2008-2011</i>	<i>188</i>
<i>TABLE 82 (CONTINUED)</i>	<i>189</i>
<i>TABLE 82 (CONTINUED)</i>	<i>190</i>
ACQUISITIONS (CONTINUED)	191
ACQUISITIONS (CONTINUED)	192
ACQUISITIONS (CONTINUED)	193
STRATEGIC ALLIANCES	194
<i>TABLE 83 BIOCHIP INDUSTRY STRATEGIC ALLIANCES, 2008-2011</i>	<i>195</i>
<i>TABLE 83 (CONTINUED)</i>	<i>196</i>
STRATEGIC ALLIANCES (CONTINUED).....	197
STRATEGIC ALLIANCES (CONTINUED).....	198
STRATEGIC ALLIANCES (CONTINUED).....	199
STRATEGIC ALLIANCES (CONTINUED).....	200
DITIGAL PCR INDUSTRY	201
<i>TABLE 84 DIGITAL PCR INDUSTRY</i>	<i>202</i>
PEPTIDE MICROARRAY INDUSTRY	203
<i>TABLE 85 PEPTIDE MICROARRAY INDUSTRY</i>	<i>204</i>
CHINA BIOCHIP INDUSTRY	205
<i>TABLE 86 CHINA BIOCHIP INDUSTRY</i>	<i>206</i>
LOAC INDUSTRY	207
<i>TABLE 87 LOAC COMPETITOR LANDSCAPE</i>	<i>208</i>
LOAC INDUSTRY (CONTINUED).....	209

CHAPTER NINE: BIOCHIPS MARKETS	210
DRIVING FORCES OF BIOCHIPS GROWTH	210
<i>TABLE 88 FORCES DRIVING BIOCHIPS GROWTH</i>	210
GROWTH IN LIFE SCIENCE R&D FUNDING	210
<i>TABLE 89 2009-2010 STIMULUS FUNDING ALLOCATED TO U.S.</i> <i>SCIENCE SPENDING (\$ MILLIONS)</i>	211
LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES	211
DEVELOPMENT OF TARGETED, PERSONALIZED MEDICINES	212
COST-CONSCIOUS HEALTHCARE SYSTEM	213
RAPIDLY AGING POPULATION IN DEVELOPED REGIONS OF THE WORLD	213
NEED FOR MORE INNOVATIVE DIAGNOSTIC TESTING FORMATS	214
ONGOING DISCOVERIES IN GENOMICS AND PROTEOMICS	214
DISCOVERY OF GENE AND SNP DISEASE ASSOCIATIONS	214
GLOBAL BIOCHIPS MARKET	215
<i>TABLE 90 GLOBAL VALUE OF BIOCHIP PRODUCTS BY</i> <i>TECHNOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	215
<i>TABLE 91 GLOBAL VALUE OF BIOCHIP PRODUCTS BY PRODUCT</i> <i>TYPE, THROUGH 2016 (\$ MILLIONS)</i>	216
<i>TABLE 92 GLOBAL VALUE OF BIOCHIP MARKET BY END USE,</i> <i>THROUGH 2016 (\$ MILLIONS)</i>	217
MICROARRAY MARKETS	218
<i>TABLE 93 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH</i> <i>2016 (\$ MILLIONS)</i>	218
DNA MICROARRAY MARKETS	219
DNA MICROARRAY MARKET BY END-USE INDUSTRY	219
<i>TABLE 94 GLOBAL VALUE OF DNA MICROARRAYS BY END USE,</i> <i>THROUGH 2016 (\$ MILLIONS)</i>	220
NONCLINICAL DNA MICROARRAY MARKET BY APPLICATION	221
<i>TABLE 95 GLOBAL VALUE OF NONCLINICAL DNA MICROARRAYS</i> <i>BY APPLICATION, THROUGH 2016 (\$ MILLIONS)</i>	221
Nonclinical DNA Microarray ... (Continued)	222
Nonclinical DNA Microarray ... (Continued)	223
<i>FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2010 (NUMBER)</i>	224
DNA MICROARRAY MARKET BY FORMAT	225
<i>TABLE 96 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT,</i> <i>THROUGH 2016 (\$ MILLIONS)</i>	225
BIOCHIPS DIAGNOSTICS MARKETS	226
BIOCHIPS DIAGNOSTIC MARKET BY INDICATION.....	226

<i>TABLE 97 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS, BY INDICATION, THROUGH 2016 (\$ MILLIONS)</i>	227
Biochips Diagnostic Market by ... (Continued)	228
Biochips Diagnostic Market by ... (Continued)	229
Biochips Diagnostic Market by ... (Continued)	230
BIOCHIPS DIAGNOSTICS MARKET BY BIOCHIP TYPE.....	231
<i>TABLE 98 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2016 (\$ MILLIONS)</i>	232
<i>TABLE 99 SEQUENCING IN DIAGNOSTICS</i>	233
BIOCHIPS DIAGNOSTICS MARKET BY ANALYSIS PERFORMED	234
<i>TABLE 100 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY ANALYSIS PERFORMED, THROUGH 2016 (\$ MILLIONS)</i>	235
BIOCHIPS DIAGNOSTICS MARKET BY FUNCTION	236
<i>TABLE 101 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY FUNCTION, THROUGH 2016 (\$ MILLIONS)</i>	236
CANCER BIOCHIPS MARKETS.....	237
CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION	237
<i>TABLE 102 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS, BY INDICATION, THROUGH 2016 (\$ MILLIONS)</i>	238
Cancer Diagnostics Biochips ... (Continued).....	239
CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE	240
<i>TABLE 103 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TECHNOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	240
<i>TABLE 104 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS</i>	241
CANCER BIOCHIPS MARKET BY ANALYSIS PERFORMED	242
<i>TABLE 105 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS, BY ANALYSIS PERFORMED, THROUGH 2016 (\$ MILLIONS)</i>	242
Cancer Biochips Market By Analysis ... (Continued)	243
CANCER DIAGNOSTICS BIOCHIPS MARKET BY FUNCTION....	244
<i>TABLE 106 GLOBAL VALUE OF CANCER DIAGNOSTICS BIOCHIPS, BY FUNCTION, THROUGH 2016 (\$ MILLIONS)</i>	244
PROTEIN MICROARRAYS MARKETS	245
<i>TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY</i>	245
PROTEIN MICROARRAYS MARKET BY TECHNOLOGY.....	246
<i>TABLE 108 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	246
Protein Microarrays Market by Technology (Continued)	247
PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT	248

<i>TABLE 109 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT THROUGH 2016 (\$ MILLIONS)</i>	248
<i>TABLE 110 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS</i>	249
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY.....	250
<i>TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2016 (\$ MILLIONS)</i>	250
EMERGING MICROARRAYS MARKETS	251
EMERGING MICROARRAYS MARKET BY TECHNOLOGY	251
<i>TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS, BY TECHNOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	251
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY.....	252
<i>TABLE 113 GLOBAL VALUE OF EMERGING MICROARRAYS, BY END USE, THROUGH 2016 (\$ MILLIONS)</i>	253
LAB-ON-A-CHIP MARKETS	253
LAB-ON-A-CHIP MARKET BY END-USE INDUSTRY.....	253
<i>TABLE 114 GLOBAL VALUE OF LAB-ON-A-CHIP DEVICES, BY END USE, THROUGH 2016 (\$ MILLIONS)</i>	254
Lab-On-A-Chip Market by End-Use Industry (Continued)	255
Lab-On-A-Chip Market by End-Use Industry (Continued)	256
Lab-On-A-Chip Market by End-Use Industry (Continued)	257
LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION	258
<i>TABLE 115 GLOBAL VALUE OF LAB-ON-A-CHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2016 (\$ MILLIONS)</i>	258
LOAC Drug Discovery and ... (Continued).....	259
LOAC Drug Discovery and ... (Continued).....	260
BIOCHIPS GEOGRAPHICAL MARKETS	261
GLOBAL VALUE OF BIOCHIPS PRODUCTS BY REGION.....	261
<i>TABLE 116 GLOBAL VALUE OF BIOCHIP PRODUCTS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	261
DNA MICROARRAY MARKET BY REGION	262
<i>TABLE 117 GLOBAL VALUE OF DNA MICROARRAYS, BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	263
PROTEIN AND EMERGING MICROARRAYS MARKET BY REGION	264
<i>TABLE 118 GLOBAL VALUE OF PROTEIN AND EMERGING MICROARRAYS, BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	264
LAB-ON-A-CHIP REGIONAL MARKETS	265
<i>TABLE 119 GLOBAL VALUE OF LOAC, BY REGION, THROUGH 2011 (\$ MILLIONS)</i>	265

CHAPTER TEN: BIOCHIPS PATENTS	266
MICROARRAY PATENTS	266
<i>TABLE 120 ISSUED DNA MICROARRAY PATENTS BY REGION, 2001–</i>	
<i>2010</i>	266
<i>TABLE 121 ISSUED PROTEIN MICROARRAY PATENTS BY REGION,</i>	
<i>2001–2010</i>	267
<i>TABLE 122 NUMBER OF PATENTS (APPLIED AND ISSUED) FOR</i>	
<i>SELECTED MICROARRAY COMPANIES</i>	268
<i>TABLE 123 PATENTS, ISSUED OR APPLIED, FOR SELECTED</i>	
<i>MICROARRAY COMPANIES</i>	269
LAB-ON-A-CHIP PATENTS	269
<i>TABLE 124 ISSUED LOAC PATENTS BY REGION, 2001–2010</i>	269
<i>TABLE 125 NUMBER OF PATENTS (APPLIED AND ISSUED) FOR</i>	
<i>SELECTED LAB-ON-A-CHIP COMPANIES</i>	270
<i>TABLE 126 PATENTS, ISSUED OR APPLIED, FOR SELECTED LAB-</i>	
<i>ON-A-CHIP COMPANIES, BY GEOGRAPHICAL REGION</i>	271
NEXT-GENERATION DNA SEQUENCING PATENTS.....	272
<i>TABLE 127 NEXT-GENERATION SEQUENCING PATENTS, BY</i>	
<i>REGION, 2001–2010</i>	272
<i>TABLE 128 NUMBER OF SEQUENCING-RELATED PATENTS</i>	
<i>(APPLIED AND ISSUED) FOR SELECTED COMPANIES</i>	273
NEXT-GENERATION DNA SEQUENCING ... (CONTINUED)	274
CHAPTER ELEVEN: COMPANY PROFILES.....	275
20/20 GENE SYSTEMS, INC.	275
ABBOTT LABORATORIES.....	276
ABTECH SCIENTIFIC, INC.	277
ADVANCED LIQUID LOGIC	278
AFFYMETRIX, INC.....	278
AFFYMETRIX, INC. (CONTINUED)	279
<i>TABLE 129 AFFYMETRIX GENECHIP DIAGNOSTIC STATUS</i>	280
AGENDIA BV.....	281
<i>TABLE 130 AGENDIA MICROARRAY-BASED DIAGNOSTICS</i>	
<i>PIPELINE</i>	282
AGENDIA BV (CONTINUED)	283
AGILENT TECHNOLOGIES, INC.	284
AKONNI BIOSYSTEMS.....	284
<i>TABLE 131 AKONNI BIOCHIP GRANTS</i>	285
ALERE TECHNOLOGIES GMBH.....	286
ALLEGRO DIAGNOSTICS INC.	287
ALMAC GROUP, LTD.	288
ANAGNOSTICS GMBH	289
ARRAYIT CORPORATION	289
ARRAY-ON GMBH	290
ASSURERX	290

AUSHON BIOSYSTEMS, INC.....	291
AUTOGENOMICS, INC.	291
AVIANA MOLECULAR TECHNOLOGIES	292
AXELA BIOSENSORS	293
AYANDA BIOSYSTEMS SA	294
BECKMAN COULTER, INC.....	294
BECTON, DICKINSON AND CO.	295
BIOCARTIS SA.....	296
BIOCEPT.....	296
BIONANOMATRIX, INC.....	297
BIOSCOR.....	298
BLUEGNOME, LIMITED	298
BODITECH MED, INC.....	299
BOEHRINGER INGELHEIM MICROPARTS GMBH	300
CALIPER LIFE SCIENCES.....	300
CAPITALBIO CORPORATION	301
CARIS MPI.....	302
CARIS LIFE SCIENCES	303
CELLIX, LTD.	303
CEPHEID	304
CHIPDX, LLC	305
CLAROS DIAGNOSTICS, INC.....	306
COMBIMATRIX CORPORATION.....	307
<i>TABLE 132 COMBIMATRIX DNA MICROARRAY PLATFORMS.....</i>	<i>307</i>
CUSTOMARRAY, INC.	308
CYTOSCALE DIAGNOSTICS, LLC	308
DECODE GENETICS.....	309
DIAGENIC ASA.....	309
<i>TABLE 133 DIAGENIC PATENT PORTFOLIO</i>	<i>310</i>
DIAGNOSTICS FOR ALL	311
DIAGNOSWISS S.A.....	311
DIGITAL GENOMICS.....	312
DNAMICROARRAY, INC.....	313
DR. CHIP BIOTECH, INC.	313
DYCONEX AG	314
ELIM BIOPHARMACEUTICALS, INC.....	314
EXACT SCIENCES.....	314
EXACT SCIENCES (CONTINUED)	315
<i>TABLE 134 EXACT SCIENCES STOOL-BASED COLORECTAL</i>	
<i>CANCER TEST VERSIONS.....</i>	<i>316</i>
EXONHIT THERAPEUTICS S.A.	316
<i>TABLE 135 EXONHIT'S SPLICE-ARRAY DIAGNOSTICS PIPELINE</i>	<i>317</i>
FALCON GENOMICS.....	318
FEBIT BIOTECH GMBH.....	319

FLUIDIGM CORPORATION	319
FULL MOON BIOSYSTEMS	320
GE HEALTHCARE LIFESCIENCES	320
GENALYTE.....	321
GENERA BIOSYSTEMS	321
GENETIC TECHNOLOGIES, LTD.	322
GENEWAVE S.A.S.	322
GENMARK DIAGNOSTICS.....	323
GENOMICA, S.A.U.....	324
GENPROBE, INC.	325
GENTEL BIOSCIENCES, INC.....	326
GOOD START GENETICS, INC.....	327
GWC TECHNOLOGIES	328
HIGH THROUGHPUT GENOMICS, INC.....	328
HOLOGIC, INC.....	329
ILLUMINA, INC.	329
ILLUMINA, INC. (CONTINUED).....	330
INOSTICS GMBH.....	331
INTAVIS BIOANALYTICAL INSTRUMENTS AG	331
IRIS BIOTECHNOLOGIES	332
IRIS INTERNATIONAL, INC.....	333
JOHNSON & JOHNSON	333
JPT PEPTIDE TECHNOLOGIES GMBH	334
KINEXUS BIOINFORMATICS CORPORATION.....	335
KONINKLIJKE PHILIPS ELECTRONICS N.V.....	336
LAB21, LTD.	336
LC SCIENCES	337
LIFE TECHNOLOGIES, INC.	338
LINEAGEN, INC.	339
LIONIX BV.....	340
LUMINEX	340
MAGARRAY, INC.....	341
MAINE MANUFACTURING	341
MAVEN BIOTECHNOLOGIES	342
MDXHEALTH S.A.	342
<i>TABLE 136 MDXHEALTH DIAGNOSTICS FOCUS</i>	<i>343</i>
METAMARK GENETICS, INC.....	344
MICRONICS, INC.	344
MINGYUAN MEDICARE DEVELOPMENT COMPANY, LTD.....	345
MIRA DX	345
MYCROARRAY.COM.....	346
NANOIVD	346
NANOSPHERE.....	347
NANOSTRING TECHNOLOGIES	348

NATURALNANO, INC.....	348
NUVERA BIOSCIENCES	349
ON-Q-ITY	349
OXFORD GENE TECHNOLOGY	350
PAMGENE INTERNATIONAL B.V.	350
PATHWORK DIAGNOSTICS	351
PATHOGENICA	351
PEPPERPRINT GMBH	352
PEPSKAN PRESTO BV.....	353
PERKINELMER	353
PERKINELMER (CONTINUED).....	354
PHALANX BIOTECH GROUP	355
PLEXERA, LLC	355
PREDICTIVE BIOSCIENCES	356
PROTAGEN AG BIOTECHNOLOGIE	356
PROTAGEN AG BIOTECHNOLOGIE (CONTINUED).....	357
PROTEIN BIOTECHNOLOGIES, INC.	358
PROTNETEOMIX SAS.....	358
QIAGEN	359
QUANTALIFE	359
QUANTRX BIOMEDICAL CORPORATION	360
QUANTERIX CORPORATION.....	360
QUEST DIAGNOSTICS	361
RAINDANCE TECHNOLOGIES, INC.	362
RANDOX LABORATORIES, LTD.	363
<i>TABLE 137 RANDOX BIOCHIPS ASSAYS PORTFOLIO</i>	<i>364</i>
RAYBIOTECH, INC.	365
RHEONIX.....	365
RIDGE DIAGNOSTICS, INC.	365
ROCHE HOLDING AG	366
SCANDINAVIAN MICRO BIODEVICES APS	367
SEEGENE, INC.	367
<i>TABLE 138 SEEGENE BIOCHIPS COLLABORATIONS</i>	<i>368</i>
SHANGHAI BIOCHIP CO., LTD.....	369
SHANGHAI BIODOOR GENE TECHNOLOGY.....	369
SHANGHAI HUAGUAN BIOCHIP CO., LTD.	369
SIALIX, INC.....	370
SIEMENS AG.....	370
SIGNAL GENETICS, LLC	371
SIGNATURE DIAGNOSTICS AG	372
SIRS-LABS GMBH	372
SKYLINE DIAGNOSTICS B.V.	373
SQI DIAGNOSTICS, INC.....	373
SOMALOGIC, INC.	374

TIANJIN BIOCHIP CORPORATION.....	374
VEREDUS LABORATORIES PTE, LTD.....	375
WAFERGEN BIOSYSTEMS, INC.	375
XAGENIC	376